Cargando…

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis

OBJECTIVE: To undertake a meta-analysis of the treatment effects of different second-line chemotherapy regimens compared with FOLFIRINOX (FOL [folinic acid], F [fluorouracil], IRIN [irinotecan], OX [oxaliplatin]) after failure of gemcitabine-based first-line therapy in patients with pancreatic cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Wenjie, Wang, Lantian, Li, Xiawei, Tang, Kezhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087258/ https://www.ncbi.nlm.nih.gov/pubmed/35481414 http://dx.doi.org/10.1177/03000605221093225

Ejemplares similares

Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
por: de Jesus, Victor H. F., et al.
Publicado: (2020)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023)

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis
por: Cho, Yo-Han, et al.
Publicado: (2017)

Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
por: Sun, Jinping, et al.
Publicado: (2017)

Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer
por: Wu, Dong-Mei, et al.
Publicado: (2017)

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review
por: Xie, Zhibo, et al.
Publicado: (2017)

Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis
por: Gan, Can, et al.
Publicado: (2017)

Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review
por: Wu, Yinying, et al.
Publicado: (2020)

Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials
por: He, Zheng, et al.
Publicado: (2017)

Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer
por: Li, Zhong-Hui, et al.
Publicado: (2022)

Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Fei, et al.
Publicado: (2021)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
por: Di Costanzo, Francesco, et al.
Publicado: (2023)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
por: Ge, Long, et al.
Publicado: (2017)

PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment
por: Su, Qiang, et al.
Publicado: (2017)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

The efficacy and safety of first-line therapies for preventing chronic post-surgical pain: a network meta-analysis
por: Ning, Jie, et al.
Publicado: (2017)

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
por: Foschini, Francesca, et al.
Publicado: (2020)

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Disease: A Meta-Analysis
por: Sun, Wenjie, et al.
Publicado: (2022)

Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis
por: Ren, Zheng, et al.
Publicado: (2017)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
por: Qian, Da, et al.
Publicado: (2023)

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer
por: Zhao, Hua-Ye, et al.
Publicado: (2016)

The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
por: Sun, Xin-Fang, et al.
Publicado: (2017)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis
por: Liu, Duanrui, et al.
Publicado: (2017)

Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
por: Abdollahi, Mohammadreza, et al.
Publicado: (2020)

Clinical efficacy of endoscopic retrograde cholangiopancreatography in the treatment of acute biliary pancreatitis: a meta-analysis
por: Tang, Dan, et al.
Publicado: (2022)

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer
por: Chen, Jiayuan, et al.
Publicado: (2021)

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
por: Sawada, Masashi, et al.
Publicado: (2020)

Efficacy and safety of non-pharmacological interventions for irritable bowel syndrome in adults
por: Dai, Yun-Kai, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure
por: Hahn, Sarah, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l1h8q3f3nrc5lo4gd3p2geh4rn